Novartis lights up radiopharmaceuticals again
The $1bn price tag for the preclinical Mariana Oncology shows that competition for assets in this space is fierce.
Bristol backs out of BET inhibition
A pipeline cull sees the US pharma joining AbbVie's exit, in the wake of Novartis’s big bet.
ASCO 2024 preview – Astra’s plenary double
Abstract titles reveal some of ASCO’s key datasets.
Third time lucky for Roche in MAGE-A4?
The Swiss company is still interested in this antigen, after discontinuing two earlier clinical projects.